Sage Therapeutics, Inc., a biopharmaceutical company headquartered in Cambridge, Massachusetts, has announced the development and commercialization of brain health medicines. Specifically, the company's product candidates include ZULRESSO, which is a CIV injection for treating postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid that has completed Phase III clinical trials for treating PPD and major depressive disorders and is in Phase II clinical trials for treating treatment-resistant depression, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound in Phase II clinical trials for treating essential tremors while also completing Phase I clinical trials for treating Parkinson's diseases and epilepsy. Additionally, SAGE Therapeutics has SAGE-689 in Phase II clinical trials for treating acute GABA hypofunction and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, in Phase II clinical trials for treating a plethora of disorders such as depression, Alzheimer's disease, Huntington's disease, schizophrenia, neuropathic pain, and attention deficit hyperactivity disorder. SAGE Therapeutics, Inc. has also partnered with Shionogi & Co., Ltd. for the development of zuranolone in Japan, South Korea, and Taiwan while also collaborating and licensing with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc., and its name was later changed to Sage Therapeutics, Inc. in September 2011.
Sage Therapeutics's ticker is SAGE
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Sage Therapeutics
It is sagerx.com
Sage Therapeutics is in the Healthcare sector
Sage Therapeutics is in the Biotechnology industry
The following five companies are Sage Therapeutics's industry peers: